Email: benjamin.waterhouse@oxon.org Hypertension is a common medical condition and a well-known risk factor for coronary heart disease, stroke, and renal disease. Resistant hypertension is defined as a systolic blood pressure (SBP) ࣙ140 mmHg despite adherence to three or more antihypertensive medications, including a diuretic. In a recent issue of The Journal of Physiology, Pijacka et al. present data looking at the surgical management of hypertension secondary to renovascular disease (Pijacka et al. 2016) .
Surgical options for managing primary hypertension focus on manipulation of the sympathetic nervous system. Proposed procedures include: vagal nerve stimulation, deep brain stimulation, carotid sinus or baroreceptor stimulation, and renal denervation. Of note, the SIMPLICITY HTN-3 trial looked at renal denervation in resistant hypertension due to the well-established physiological role of the kidney on blood pressure (Bhatt et al. 2014) . The outcomes of the trial were disappointing despite the promising physiological rationale. No significant differences were observed in the SBP or 24-h ambient blood pressure monitoring readings between the renal denervation and the sham group. However, certain methodological concerns have been raised, such as the potential for incomplete or ineffective denervation, and so this remains a contender for surgical intervention.
Carotid sinus denervation: does it work?
Another surgical option of interest is carotid sinus denervation (CSD), which is also showing promise. Pijacka et al. demonstrated a significant reduction in mean arterial pressure (MAP) of 6 mmHg (P = 0.02) in two kidney one clip (2K1C) rats undergoing CSD (Pijacka et al. 2016) .
When comparing this with non-denervated 2K1C rats they found that CSD reduced MAP by 14 mmHg (P < 0.01). Previously, the same group performed an analogous study looking at the role of CSD in spontaneously hypertensive rats (SHRs) (Abdala et al. 2012) . The similar methodology in both studies demonstrates the reproducibility and improves the credibility of the results. They found a reduction in MAP of 15 mmHg (P < 0.05) after SHRs underwent CSD. Both studies showed a reduction in MAP after CSD, but would this be deemed clinically significant when taking into account the modest reduction and the risks of an invasive procedure in patients otherwise managed with medication? If this were to be undertaken in humans, would surgeons be more cautious in performing CSD? Would this lead to less extensive denervation?
Studies in human participants have tended to look at the effect of carotid body resection rather than CSD. A study by Nakayama dating back to 1961 looked at surgically removing the carotid body and the effect of this on bronchial asthma (Nakayama, 1961) . They dissected the entire carotid body from the bifurcation of the carotid artery opposed to resecting its nervous supply. The rationale behind this was to avoid unnecessary damage to surrounding nerves. An incidental finding of this study was the effect on blood pressure. Interestingly, they found this to have little effect on normotensives, a reduction in blood pressure in hypertensives, and an increase in blood pressure in hypotensive patients. However, this study does not quantify this reduction and therefore, it is difficult to determine the clinical significance. They suggested that removal of bilateral carotid bodies compared to a single unilateral carotid body has little effect on asthma, but no comment was made on blood pressure. A more recent study in 2016 looking at unilateral carotid body resection in humans with resistant hypertension claims to be the first prospective feasibility and safety clinical trial on unilateral carotid body dissection for the treatment of high blood pressure (Narkiewicz et al. 2016) . They divided patients into responders and non-responders. Eight patients responded (53%) with an average reduction at 1 month of 52 mmHg (P = 0.006) compared to office systolic blood pressure at screening. CSD appears to reduce MAP; however, questions are raised as to whether this can be safely implemented in humans and whether this reduction has the clinical significance to warrant the risks.
Carotid sinus denervation: what are the risks?
Surgical management is perceived as more invasive than pharmacological intervention and often lacks the reversibility of simply stopping a medication. Careful consideration of safety and unintentional effects of this new strategy are essential. These risks can be broadly grouped:
(1) those common to all surgical interventions such as infection or complications of sedation/anaesthesia; (2) those specific to surgery in the region of the carotid bifurcation such as damage to the hypoglossal nerve; and (3) those specific to life without a functioning carotid body. The carotid body's proportionally high blood flow per gram of tissue is often quoted as a surrogate marker of its importance, so can we simply live without them following bilateral resection? Removing a physiological feedback system feels counterintuitive. One could postulate that at times of increased oxygen demand or poor perfusion pressures the blunting of such mechanisms could be damaging to physical performance or even survival. Redundancy in the mechanisms for increasing respiration and circulation during exercise has been appreciated since the time of Krogh and Lindhard. However, in conditions such as high altitude where alveolar hypoxia may be the primary disruption a maladaptive response may ensue. Earlier work of the authors suggests this not to be the case; denervated SHR showed no deleterious changes in respiratory function when reducing the fraction of inspired O 2 to 10% (Abdala et al. 2012) .
In conditions such as sepsis, antihypertensive medications are frequently withheld for a transient period to allow native homeostatic mechanisms overcome the acute physiological challenge unopposed. Would a patient without a carotid body be able to compensate? Pijacka et al. actually demonstrate an improved Journal Club J Physiol 595.8 response to nitroprusside-induced vasodilatation in their renovascular rat model, which suggests that this mechanism is not lost (Pijacka et al. 2016) . The most concerning adverse effect described in the Abdala et al. study is the transient apnoeic episodes experienced by some rats immediately after the second CSD (Abdala et al. 2012) . Even more concerning is that some rats required resuscitation. However, there were no rat mortalities. Would the theoretical risk of transient apnoea and potential arrest be acceptable in humans?
Comfort can be found in the work of Nakayama; pursuing the removal of sympathetic drive in the bronchoconstriction of asthma he reports the removal of carotid bodies from thousands of patients with low rates of complication (Nakayama, 1961) .
Carotid sinus denervation: does is work for everyone?
In this era of personalised medicine appropriate patient selection is key. Narkiewicz et al. performed unilateral carotid body resection in 15 patients with resistant hypertension; they found themselves left with responders and non-responders (Narkiewicz et al. 2016) . Despite caution being required when dichotomising continuous data, their work suggests predictive factors for potential responders that can be explored further in future prospective studies. This could help us avoid exposing those unlikely to benefit to the risks of surgery such as they are. The baseline respiratory characteristics of these two small groups were found to differ giving a potential indication of those in whom the carotid body is behaving pathologically. Curiously, responders had a higher respiratory rate and lower tidal volume at baseline; over-activation of the carotid bodies would be expected to produce the former but not necessarily the latter. A greater hypoxic ventilatory response was also seen amongst the responders. Interestingly the baseline muscle sympathetic nerve activity (MSNA) did not differ, but a post-operative reduction in MSNA did correspond to blood pressure response. It could also be suggested that microneurography is in its own right invasive for use as a screening tool.
It has been demonstrated, in rat and human subjects alike, that hyperoxia can produce a transient reduction in blood pressure and a corresponding drop in MSNA. It is of particular interest that these effects are seen in patients with essential hypertension and in the spontaneously hypertensive rat yet are absent in normotensive humans and wild-type Wistars. It may be possible to utilise this response to evaluate if carotid body tonicity is a prominent factor in a patient and predict their response to a more permanent, surgical denervation (Narkiewicz et al. 2016) .
Carotid sinus denervation: is it suitable for everyone?
Assuming matters of efficacy to be addressed, for which patient population would such an intervention be most appropriate? The most obvious answer is those with resistant hypertension or taking the maximum tolerated dose with suboptimal results. A question commonly encountered by the authors when commencing antihypertensive medications de novo is: 'So how long will I be taking these?' and the uncomfortable answer is forever. Could carotid body surgery be an alternative to lifelong pharmacological therapy? If it could replace the need for mediations entirely this may well be a preferable alternative. Supporting this, the work of Narkiewicz et al. demonstrated a reduction in whole dose equivalents of antihypertensive medications amongst their responders (Narkiewicz et al. 2016) . Furthermore, it addresses the issue of poor compliancea common mimic of treatment resistance. The proof of principle study discussed above included CT scanning to carefully define anatomy during screening (Narkiewicz et al. 2016) . Those with high carotid bifurcations, significant atheroma, aberrant anatomy, or inaccessible carotid bodies were excluded; these principles help to guide safe patient selection but will also limit the applicability of the technique.
Conclusions
This building body of evidence could support a change in how we manage this increasing common disorder with the potential to provide substantial reductions in cardiovascular risk at the population level. This work could alternatively be viewed as an elegant proof that the carotid body represents a potentially efficacious pharmacological target in primary hypertension.
